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Abstract: Poly (ADP-ribose) polymerases (PARPs) play an important role in various cellular processes,
such as replication, recombination, chromatin remodeling, and DNA repair. Emphasizing PARP’s role
in facilitating DNA repair, the PARP pathway has been a target for cancer researchers in developing
compounds which selectively target cancer cells and increase sensitivity of cancer cells to other
anticancer agents, but which also leave normal cells unaffected. Since certain tumors (BRCA1/2
mutants) have deficient homologous recombination repair pathways, they depend on PARP-mediated
base excision repair for survival. Thus, inhibition of PARP is a promising strategy to selectively
kill cancer cells by inactivating complementary DNA repair pathways. Although PARP inhibitor
therapy has predominantly targeted BRCA-mutated cancers, this review also highlights the growing
conversation around PARP inhibitor treatment for non-BRCA-mutant tumors, those which exhibit
BRCAness and homologous recombination deficiency. We provide an update on the field’s progress
by considering PARP inhibitor mechanisms, predictive biomarkers, and clinical trials of PARP
inhibitors in development. Bringing light to these findings would provide a basis for expanding the
use of PARP inhibitors beyond BRCA-mutant breast tumors.
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1. Introduction
Breast cancer is among the three most common cancers worldwide. It is also consistently the
leading cause of disability-adjusted life-years (DALYs) and the leading cause of death in women [1].
Breast cancer comprises highly heterogeneous cancer sub-types, due to distinct genetic profiles
manifesting in broad clinical presentations across patient populations. Breast cancers can be divided
into molecular subtypes based on the presence of hormone receptors, estrogen receptor (ER) and
progesterone receptor (PR), and receptors such as human epidermal growth factor receptor II
(HER2) [2]. Triple-negative breast cancers, also called TNBC (ER negative, PR negative, and HER-2
negative), occur in approximately 17% of breast cancers, are aggressive cancers, and are associated with
early development of metastasis [3]. Approximately 85% of all breast cancers are hormone receptor
(HR) positive and can be treated with hormone therapies such as Tamoxifen, aromatase inhibitors,
Trastuzumab (Herceptin), and others [3]. On the contrary, treatment of TNBC remains challenging,
as this sub-type does not overexpress receptors for which hormone therapies can target. Additionally,
HR-positive breast cancers, which initially responded well to hormone therapy, can develop into
recurrent tumors with downregulation or loss of ER or PR, a finding which may contribute to resistance
to endocrine therapy and highlights the challenges associated with breast cancer treatment [4–6].
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BRCA mutation status is thus one phenomenon being studied for developing targeted therapies
against TNBC and other breast cancer subtypes. Patients with TNBC have a higher prevalence of
BRCA1/2 mutations; however, prevalence varies from 10% to 42% [7]. Conversely, over 80% of breast
cancer patients with a BRCA1 mutation have TNBC [8]. BRCA-mutation associated tumors lack
the homologous recombination repair (HRR) pathway, which repairs double-strand breaks (DSB).
Published clinical studies suggest that germline BRCA mutation-associated (gBRCAm) breast cancers
are more sensitive to DNA-damaging therapies like poly (adenosine diphosphate ribose) polymerase
(PARP) inhibitors [9]. The FDA (Federal Drug Administration) has approved use of PARP inhibitors
(PARPi) for treatment of ovarian, prostate, pancreatic, fallopian tube, and peritoneal cancers [10].
More recently in 2018, two PARPi, olaparib and talazoparib, were approved as monotherapies for
BRCA-mutated HER2-negative metastatic breast cancer [11,12]. With the field of PARP inhibitor
therapy rapidly advancing, PARPi warrant further clinical evaluation for treating the heterogeneous
nature of breast cancer subtypes.
This review article explores the therapeutic potential of PARPi in cancer therapy and the use of
PARPi beyond BRCA-mutant tumors, such as those with BRCAness and homologous recombination
deficiency. An emphasis is placed on the components of the PARP pathway which mediate selective
cytotoxicity of PARPi, predictive biomarkers, and clinical trials involving PARPi for the treatment of
breast cancers. In this review, we also discuss the resistance mechanisms emerging against PARPi.
2. PARP Inhibitors as Therapeutic Intervention
PARP-1 and PARP-2 are the most extensively studied PARPs for their role in DNA damage
repair. When induced by DNA lesions, PARP1 detects the DNA damage break and catalyzes the
addition of poly (ADP-ribose) (PAR) chains to target proteins. This post-translational modification
catalyzed by PARP, known as PARylation, mediates the recruitment of additional DNA repair
factors to the DNA lesion [13,14]. Four known domains of PARP-1 facilitate DNA repair: (1) the
amino-terminal DNA-binding domain containing two zinc-finger motifs, which recognize DNA strand
breaks; (2) domain B, which contains a nuclear localization signal; (3) a central auto-modification
domain; and (4) a carboxyl-terminal catalytic domain (CAT) that binds oxidized NAD+ [13,15–18].
A distinction is made that some researchers include the WGR (Trp, Gly, Arg) domain as part of
CAT [16], while other researchers list the WGR and CAT as two separate entities (this distinction is
further revisited in Section 2.1 of this paper) [19]. A 2012 review by Gibson and Kraus highlights the
complexity of PAR and PARP interaction and the necessity of PARylation to disrupt protein–protein and
protein–DNA interactions [20]. In addition, PAR is required for protein localization and formation of
functional molecular scaffolds [20]. Another review from 2008 highlights research which examines the
role of NAD+ concentration in compaction or decompaction of chromatin by PARP-1 [21]. In focusing
on PARP’s role in DNA repair, upon PARP binding to a DNA strand break, PARylation is stimulated
more than 500-fold [15,18]. In a complex mechanism involving recruitment of essential repair proteins,
which include, but are not limited to, DNA ligase III, XRCC1, BARD1, γH2AX, 53BP1, BRCA1,
and others, PARP-1 in conjunction with PARP-2 and PARP-3 facilitate repair via multiple repair
processes mentioned below. The involvement of these PARPs in repair mechanisms have been reviewed
extensively by Beck et al. [22].
Although our understanding of PARP is largely connected to HRR, PARP-1 also influences
multiple repair pathways that can be utilized by BRCA1/2-deficient cells. While homologous
recombination is the principle DSB repair mechanism, in homologous recombination-deficient cells,
such as those with BRCA1/2 mutations, DNA damage is either repaired with low fidelity repair
mechanisms or is not repaired at all [19]. These alternative pathways include non-homologous
end-joining (NHEJ), alternative non-homologous end-joining (aNHEJ), and single-strand annealing
(SSA), pathways which are generally considered to be error-prone compared to HRR [23]. NHEJ
also plays a large role in DSB repair; in contrast to HRR, NHEJ does not require a homologous
template for DNA repair [24]. NHEJ can be categorized into two subtypes, classical NHEJ or aNHEJ,
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which have varying consequences for genome integrity. One potential reason for the perceived
fallibility of classical NHEJ may be because the NHEJ machinery is flexible in dealing with a wide
range of DSB structures [25]. Alternatively, aNHEJ is involved in repairing junctions with complex
insertions/deletions, although research has shown that aNHEJ joins DSBs on different chromosomes,
leading to chromosomal translocations and mutagenic consequences [26]. SSA also repairs DSBs,
but extensive resection occurs. Following annealing at direct repeats flanking the DSB and 3’ flap
removal, single-strand gap filling and ligation results in large deletions [27]. Although PARP and HRR
are largely intertwined in the context of PARP inhibitors, the existence of alternative repair pathways
may explain how cells can develop resistance to PARP inhibitors.
In the presence of DNA damage and a PARP inhibitor, PARP inhibitors prohibit PARylation from
occurring and PARP-1 remains tightly bound to damage sites. This action in which the binding affinity
of PARP-1 to damaged DNA is increased is called PARP trapping [28]. Murai et al. propose two
mechanisms by which PARPi trap PARP, including the inhibition of PARylation or a reverse allosteric
mechanism in which PARPi binds to NAD+ and enhances the binding of DNA to PARP’s zinc finger
domain [28]. As a result of PARP trapping, the following occur: replication fork collapse, unrepaired
DNA damage, and cytotoxicity (Figure 1) [29]. The synthetic lethality mediated by PARP inhibition
and homologous recombination deficiency (HRD) leads to cell death. Early studies demonstrate
that cells that are deficient in BRCA1 or BRCA2 display increased sensitivity to PARP inhibitors
by about 1000-fold [9]. Thus, PARP inhibition is a promising therapeutic strategy for homologous
recombination-deficient tumors, such as those associated with BRCA mutations, and the use of PARPi
can potentially be expanded to tumors without BRCA mutations.
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Figure 1. PARP pathway overview. Cellular stress such as oxidative stress from reactive oxygen
species causes DNA damage in the form of single- and double-strand breaks. Under normal conditions,
the PARP pathway is activated. ADP-ribose units are recruited to sites of DNA strand breaks in a process
known as PARylation. With the assistance of PARP and other DNA repair enzymes, repair of DNA
strand breaks occurs, and the cell remains viable. This figure provides an overview of what happens in
the presence of a PARP inhibitor in BRCA-mutated cells which have defects in the homologous
recombination repair pathway. The PARP inhibitor mediates inhibition of PARylation, thereby
preventing repair of DNA strand breaks via the PARP pathway or the homologous recombination
repair pathway. This synthetic lethality in which both repair pathways are nonfunctional contributes
to unrepaired single-strand breaks and double-strand breaks; accumulation of double-strand breaks
ultimately leads to apoptosis and cell death. (DSB = double-strand break; PARP = poly (ADP-ribose)
polymerase; ROS = reactive oxygen species)
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2.1. Selective Cytotoxicity of PARP Inhibitors
In looking at how PARP inhibition may mediate selective cytotoxicity, it is essential to revisit the
relative contributions of both catalytic domain function and PARP trapping. Firstly, previous research
has emphasized the importance of particular PARP-1 domains (out of the domains mentioned in the
previous section), which are essential for formation of interdomain contacts linking the DNA domain
interface to CAT. These domains include Zn1 and Zn3 (part of the DNA-binding domain) and WGR
which are linked to CAT [19]. As mentioned previously, there is discrepancy as to whether or not
WGR is part of the CAT domain. A DNA-dependent mechanism, mediated by the automodification
domain of PARP-1, involves binding of Zn1, Zn3, and WGR to a DNA strand, resulting in distortion
of the hydrophobic core of the helical subdomain (HD) of CAT. HD distortion results in decreased
thermal stability of CAT, thereby increasing CAT domain exposure. However, in the folded state, HD
inhibits catalytic activation of PARP-1 [30]. More recent research further probes the interaction of CAT
and NAD+. Results show that while PARP-1 alone has less access to NAD+, thus accounting for the
minimal level of unstimulated PARP-1 activity, PARP-1 when bound to DNA strand breaks allows
NAD+ to access CAT [31]. When the NAD+ binding site is occupied, distorted HD is stabilized and
affinity for DNA strand break damage is increased [31]. Thus, the network of multi domain assembly
is critical for DNA-dependent activation of full-length PARP-1. Altered domain interfaces are the sites
at which PARP inhibitors can disrupt allosteric interaction, thereby rendering PARP-1 nonfunctional.
Secondly, selective cytotoxicity of PARPi may be mediated by PARP trapping, a term coined by
Pommier and colleagues to refer to the effect of PARPi sequestering both PARP-1 and PARP-2 on
PARP–DNA complexes, blocking the recruitment of additional DNA repair proteins [28]. This study is
one of the first to examine the idea that PARPi treatment results in varying degrees of toxicity, based
not on its potency to inhibit PARP catalytic activity but rather on its ability to stabilize PARP-DNA
complexes. In the presence of both PARPi and damaged DNA, the distribution of PARP-1 shifts from
nuclear-soluble to chromatin-bound [28]. A 2015 study by Hopkins et al. further expands upon the
PARP trapping concept but instead supports that catalytic inhibition and PARP trapping are, in fact,
positively correlated in biochemical systems but not in cells [32]. Furthermore, these studies reveal that
although the developed PARP inhibitors (olaparib, niraparib, rucaparib, talazoparib, and veliparib)
have shown effective inhibition of PARP-1 and -2, they differ in their ability to cause PARP trapping,
with talazoparib having the highest trapping activity [32–34]. Accordingly, it appears that the cytotoxic
mechanism as it relates to PARP trapping may be dependent on the use of PARPi in monotherapy or
combination therapy. For example, when PARPi is combined with topoisomerase I (TOP1) inhibitors,
cytotoxicity appears to be less attributed to PARP-1 trapping [35]. On the other hand, the activity
of PARPi plus alkylating agents, such as temozolomide, appears to be largely attributed to PARP
trapping, as demonstrated by quantification of PARP–DNA complexes following treatment [36].
Recent research elaborates upon the cellular consequences of PARP trapping and establishes
the connection between ribonuclease (RNase) H2 deficiency and hypersensitivity to PARPi [37].
RNase H2 is involved in ribonucleotide excision repair. The evidence gathered by Zimmerman et al.
shows that PARP inhibition requires the formation of trapped PARP1-DNA adducts in order to be
synthetic lethal, as confirmed by double mutant RNASEH2AKOPARP1KO cells. Their data further
supports that ribonucleotides may be a major source of PARP trapping. They propose that both the
canonical ribonucleotide excision repair (RER) pathway and TOP1-mediated ribonucleotide cleavage
are involved in trapping of DNA lesions that impede DNA replication and ultimately lead to cell death.
These mechanistic findings have further implications for the use of PARPi in combination with
other anti-cancer agents and when considering toxicity in clinical applications.
3. BRCAness and Homologous Recombination Deficiency (HRD)
Accordingly, the connection between TNBC and BRCA mutations has been widely studied and
utilized as a prognostic marker for TNBC therapy. BRCA1 tumors are often grade 3 ductal carcinomas
and ER−, while BRCA2 tumors are often ER+ and lower grade with high mitotic rates [38,39]. However,
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another aspect complicating TNBC therapy is BRCAness, which defines molecular and phenotypic
characteristics that TNBC sporadic cancers share in common with BRCA-mutated cancers [8].
Tumors which exhibit BRCAness may also exhibit loss-of-function alterations causing a
dysfunction in the HRR pathway, even though they do not have a mutation in the BRCA gene [40].
The application of mutational signatures, which are patterns of somatic mutations that reflect
levels of DNA damage and repair processes, to the understanding of BRCAness is increasingly
studied [41,42]. Numerous studies have revealed mutational signatures associated with breast cancer,
namely signatures 1, 2, 3, 8, and 13, and also provide a mutational characterization of cancers with
BRCA1 and BRCA2 [43,44]. Polak et al. explores signature 3, a mutational signature prevalent in
tumors with BRCAness [45], and finds altered expression of PALB2 and RAD51, genes important for
the HRR pathway. Additionally, signature 3 was found in tumors with both germline and somatic
BRCA1 and BRCA2 mutations [45]. Thus, the role of signature 3 as a potential biomarker (more on
mutational signatures in Section 4.1) needs to be investigated further, but signature 3 can help guide
development of BRCAness-targeting therapies.
Identifying HRD in tumors is complex and involves detecting mutational alterations in the
genome. Alterations can come in the form of germline mutations in HRR-associated genes, such
as PALB2, BARD1, and RAD51D [46]. Somatic mutations may also arise in HRR-associated genes;
however, germline mutations are more common than somatic mutations in BRCA1- and BRCA2-
mutated cancers [43]. BRCAness and HRD also involves methylation of the BRCA promoter, which
appears to be most common in TNBCs [8,40,47]. Breast tumors with BRCA1 methylation also show
higher histological grade, like that of BRCA1-mutated tumors [8]. It was demonstrated that patients
with BRCA-mutated tumors had a significantly higher pathological complete response (pCR) to
chemotherapy (63%), while tumors with BRCAness only had a pathological complete remission rate
of 35% [8].
Additional contributors to HRD involve copy number alterations (CNA), and early research
has revealed that the basal-like subtype of breast cancer has higher numbers of gains/losses, while
the luminal B subtype has more frequent high-level DNA amplification [48]. DNA microarrays and
comparative genomic hybridization (CGH) can be used to identify genome instability comparing test
DNA and control DNA [49]. Chromosomal rearrangements, such as inversions, translocations, and
recombination, are largely implicated in loss of heterozygosity (LOH) and allelic imbalance, which can
be studied using single-nucleotide polymorphism (SNP) analysis [50]. Figure 2 summarizes the major
biomarkers of HRD.
Increasingly studied is the involvement of microRNAs (miRNAs) targeting DNA repair machinery
as a potential therapeutic target for BRCAness. Overexpression of miR-182 sensitizes MDA-MB-231
TNBC cells to PARPi by downregulating BRCA1 [51]. Another study shows that miR-151-5p is
upregulated in PARP1-overexpressing BRCA-mutated and sporadic breast tumors, which eventually
could be considered as BRCAness tumors. This miRNA targets the coding sequence of SMARCA5,
an ATP-dependent chromatin remodeler [52]. Additionally, numerous studies have explored the
concept of BRCAness induction followed by treatment with PARPi. TGFβ induces BRCAness by
downregulating BRCA1, ATM, and MSH2, genes involved in DNA repair, through a miRNA-mediated
mechanism [53]. Another approach that has been explored is inducing BRCAness with histone
deacetylase inhibitors [54,55].
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Figure 2. Homologous recombination deficiency (HRD) and genomic alterations. (a) Both germline
mutations and somatic mutations involving HR-related genes, including BRCA1 and BRCA2, may be
associated with HRD. (b) Promoter methylation involves addition of a methyl group to CpG islands,
which ultimately silences gene expression. This is an epigenetic mechanism implicated in HRD.
(c) Copy number aberrations/alterations alter chromosomal structure and are a hallmark of HRD.
(d) Genomic scars are examined and can be scored to measure the level of HRD phenotype in a sample.
(e) Mutational signatures are patterns of base pair mutations that measure levels of DNA damage in a
sample. Pictured here is a representation of signature 3, a mutational signature highly prevalent in
tumors with BRCAness and also one of a few distinct mutational signatures found in breast cancer.
Signature 3, among other mutational signatures, was characterized in 2013 by Alexandrov et al. [42].
4. Predictive Biomarkers in Breast Cancer
As PARPi selectively target HR-deficient tumors, particularly in patients who bear germline
BRCA1 or BRCA2 mutations, reliable biomarkers are needed to accurately select patients with HR
deficiency who would greatly benefit from PARPi-based anticancer therapies. There currently is no set
method to determine whether a patient will respond to PARPi. However, in vitro and in vivo studies
also demonstrate that HRD is not the only factor which determines sensitivity to PARPi. Thus, various
biomarkers beyond tumor DNA repair status have also been explored.
One well-studied phenomenon of HRR is RAD51 localization to the nucleus after damage to
DNA occurs. RAD 51 nuclear foci do not form in cells that lack functional BRCA1/2 or other functional
HRR components [56]. In establishing a connection between patient breast tumor samples and
RAD51 formation, breast tumor samples were irradiated and subjected to RAD51 ionizing radiation
induced foci (IRIF) analysis [57]. Over 10% of tumors showed impaired RAD51 IRIF formation from
hypermethylation of the BRCA1 promoter, which was also correlated with BRCA gene status and
TNBC. RAD51 IRIF-negative tumors were sensitive to olaparib treatment. One major downside of
the RAD51 IRIF assay is that it can only be performed on fresh tumor material. A more recent study
establishes a connection between the presence of RAD51 nuclear foci formation and PARPi resistance
in gBRCAm breast and ovarian tumors [58]. There are two major limitations to using RAD51 foci as a
biomarker for HRR proficiency: (1) RAD51 foci formation must be induced by DNA damage, such as
damage cause by PARPi; and (2) RAD51 is only detected in the S and G2 phases of the cell cycle [59].
Recently, genomic analysis revealed that two BC cell lines exhibit BRCAness, HCC70 (TNBC,
basal, BRCA wt) and MDA-MB-468 (TNBC, basal, BRCA mutant) [60]. The other cell lines in this study,
MCF7 (luminal A), MDA-MB-231 (TNBC, mesenchymal, BRCA wt (Wildtype)), and MDA-MB-436
(TNBC, mesenchymal, BRCA mutant), did not show a BRCAness phenotype but were categorized
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under sporadic-like breast tumors. In BRCA1-like cell lines compared with BRCA1 wt cell lines, nine
metabolites were identified to be significantly under-represented [60].
4.1. Sequencing-Based Methods
HRD scores are capable of detecting HRR defects and are reported to be predictive of response
to PARPi in patients with TNBC and BRCA1/2-mutated breast or ovarian cancers [47,61]. HRD score
has previously been shown to be predictive of tumor response to neoadjuvant chemotherapy [62,63].
Myriad Genetics, Inc. and Timms et al. developed a next-generation sequencing-based HRD assay
using SNP profiling. This combines three different DNA-based metrics of genomic instability: HRD-loss
of heterozygosity score (HRD-LOH) [61], HRD-telomeric allelic imbalance score (HRD-TAI) [64], and
HRD-large-scale state transition score (HRD-LST) [65]. The HRD scores in their 2014 study examined
breast tumors representing TNBC and all ER/HER2 subtypes, and showed a significant association
with BRCA1/2 deficiency regardless of subtype or stage [47]. The presence of high HRD scores in
BRCA1/2-intact tumors also strongly suggests that alternate mechanisms account for HRD [47].
Unique mutational signatures result from the use of error-prone DSB repair mechanisms in HRD
tumors. In a 2013 study by Alexandrov et al., 20 distinct, conserved mutation signatures were present
across multiple cancer types [42]. These signatures are characterized by the presence of small deletions
of up to 50 bp. In breast cancer specifically, signatures 1B, 2, 3, 8, and 13 were prevalent and strongly
associated with BRCA1/2 mutations. These signatures may be examined to identify tumors with a
BRCAness phenotype and presumably predict response to PARPi therapy [50], although genomic
scars in gBRCAm tumors may persist after restoration of HRR function [50,66]. Other gene-specific
sequencing strategies include multiplex-ligation-dependent probe amplification (MLPA) [67] and
identification of transcriptional metagene signatures [68].
HRDetect is a whole genome sequencing-based predictor that was developed to accurately detect
BRCA1/2-deficient breast tumor samples [66]. In a 2017 paper describing HRDetect, six predictive
parameters were observed in distinguishing BRCA1- and BRCA2-deficient tumors, in order of
decreasing weight: microhomology-mediated deletions, base-substitution signature 3, rearrangement
signature 5, rearrangement signature 5, HRD index, and base substitution signature 8 [66]. This final
predictor, termed HRDetect, was applied to a cohort of 560 cases of breast cancer and showed a 98.7%
of detecting BRCA1/2-deficient tumors. This method analyzes multiple mutational signatures as a
predictor, which is advantageous, the authors say, to using the HRD score. Additionally, HRDetect is
able to distinguish BRCA1-deficient from BRCA2-deficient tumors.
Numerous diagnostic tests have been explored to predict sensitivity to PARPi. Myriad Genetics,
Inc. has also developed BRACAnalysis CDx, the first FDA approved companion diagnostic for
treatment in patients with gBRCAm ovarian cancer and metastatic breast cancer. BRACAnalysis
CDx is a diagnostic test which utilizes sequencing and deletion/duplication analysis to identify
germline mutated BRCA1/2 genes [69]. The effectiveness of BRACAnalysis CDx was established
based on the OlympiAD trial population (NCT02000622), leading to the FDA approval of olaparib
for ovarian cancer patients with gBRCAm in 2014 [69,70]. Foundation Medicine’s T5 NGS assay
(Cambridge, MA, USA) was used to assess genomic LOH when predicting response of patients
with recurrent ovarian carcinoma to rucaparib [71]. Other diagnostic tests include Foundation
Medicine’s FoundationOne CDx, the first comprehensive genomic profiling test for all solid tumors,
and MSK-Impact, which is capable of detecting protein-coding mutations, copy number alterations,
and selected promoter mutations and structural rearrangements in 341 cancer-associated genes [72,73].
The main takeaway is that, along with the identification of predictive biomarkers, whole-genome
sequencing and sequencing-based diagnostic or predictive methods can support the implementation of
using PARPi for precision medicine. However, these studies also reveal that sensitivity to PARPi is not
limited to those with BRCA1/2 mutations. The challenge of finding predictive biomarkers for response
to PARPi underscores the urgent need to develop targeted therapies to approach the heterogeneous
nature of breast cancer.
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5. PARP Inhibitors as a Single Agent
In 2005, through animal model experiments, Bryant et al. and Farmer et al. confirmed the
use of PARP inhibitors as a target therapy in BRCA-mutated cells [9,74]. Subsequently, following
strong preclinical findings demonstrating the therapeutic potential of PARP inhibitors, olaparib showed
durable antitumor responses in patients with advanced gBRCAm ovarian, breast, or castration-resistant
prostate cancer [75,76]. Olaparib was the first PARPi approved by the FDA in December 2014 for use
as monotherapy in patients with gBRCAm advanced ovarian cancer. Since then, the field of PARPi
monotherapy has rapidly advanced, with additional FDA approvals of niraparib (March 2017) and
rucaparib (April 2018) for maintenance treatment of BRCA-mutated ovarian cancer. In 2018, two PARP
inhibitors were approved for gBRCAm metastatic breast cancer, olaparib and talazoparib.
6. Combination Strategies with PARP Inhibitors
Previous in vitro studies have examined various mechanisms to increase tumor sensitivity to and
to maximize the efficacy of PARPi through combination therapy. A critical concern is the development
of resistance to PARPi therapy (please refer to Section 8, “Acquired resistance to PARP inhibitors”),
which also can be mediated through the use of PARPi in combination with other agents. Additional
concerns include increased cytotoxicity or adverse events with combination therapy, which has been
addressed in other reviews.
The effect of PARPi on cancer cells is enhanced in combination with DNA demethylating
agents [77]. This study showed that PARP-1 and DNA methyltransferase 1 (DNMT1) form a complex
and are recruited to sites of DNA damage. Combination drug administration yielded increased
cytotoxicity and frequency of DSBs compared to either PARPi or DNMTi alone. In vivo, TNBC
xenografts treated with a DNMTi–PARPi combination demonstrated a significant reduction in tumor
burden in comparison to controls or monotherapy [77].
A 2012 study examines the efficacy of PARP inhibitors in patient populations other than those
with BRCA-mutant tumors. This study focuses on BRCA-proficient TNBC and sensitizes these cells to
PARP inhibition via inhibition of the phosphoinositide 3-kinase (PI3K) pathway [78]. Under normal
conditions, PI3K stabilizes DNA repair by interacting with the HRR complex [79]. Treatment of
BRCA wt TNBC cells with BKM120, a pan-PI3K inhibitor, resulted in downregulation of BRCA1/2
along with an increase in PAR proteins. Combination of olaparib, a PARPi, with BKM120 showed a
significant reduction in BRCA wt TNBC cells. In patient-derived primary tumor xenografts, the TNBC
models studied, which demonstrated downregulated BRCA expression upon BKM120 treatments, also
showed an increase in PAR levels. While olaparib monotherapy was ineffective in these xenograft
models, BKM120 and olaparib combination yielded significantly decreased tumor growth. Of note,
BRCA downregulation and PARP activation was required for the dual effect of PI3K inhibition and
PARP inhibition.
Many additional pathways have been studied to increase sensitivity of tumor cells to PARP
inhibitors. As mentioned previously, breast cancer heterogeneity is challenging when it comes to
treatment and prevention. Understanding the mechanistic pathways whereby PARP is affected is
crucial to effectively target both BRCA wt and BRCA-mutant breast tumors.
7. Clinical Development of PARP Inhibitors in Breast Cancer
The following discussion examines developed PARP inhibitors that have shown effective and
comparable inhibition of PARP-1 and PARP-2. However, these PARP inhibitors differ in PARP-trapping
activity. Discussions of PARPi are organized in order of increasing PARP-trapping activity, from
veliparib with the least PARP-trapping activity to talazoparib with the most PARP-trapping activity,
and rucaparib, niraparib, and olaparib in between [28,32–34].
There are over 150 completed, recruiting, or current registered clinical trials (clinicaltrials.gov)
involving the PARP inhibitors niraparib, olaparib, rucaparib, talazoparib, and veliparib. A majority of
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these clinical trials involve PARPi as monotherapy in patients with BRCA-mutated tumors, especially
with those involving breast cancer. Several clinical studies in ovarian cancer; however, highlight
the utility of PARPi to treat non-BRCA-mutated tumors: ARIEL2 (NCT01891344) [80], ARIEL3
(NCT01968213) [71], NOVA (NCT01847274) [81], Study 19 (NCT00753545) [81].
Combination trials include PARPi with platinums, taxanes, ATM (Ataxia Telangiectasia Mutated
Protein) inhibitors, ATR(Ataxia Telangiectasia and Rad3-related Protein) inhibitors, Wee1 inhibitors,
and PI3K inhibitors. Combination immune therapy is explored as well. Thus far, olaparib, niraparib,
and rucaparib have been FDA approved for use as maintenance therapy in recurrent ovarian cancer.
Only olaparib and talazoparib have been approved by the FDA for treatment of gBRCAm breast cancer.
7.1. Veliparib (ABT-888)—AbbVie
7.1.1. Monotherapy
A phase I trial completed in 2014 showed evidence of veliparib’s anti-tumor activity for patients
with gBRCAm advanced TNBC and ovarian cancers (NCT00892736) [82]. In this study, objective
response rate (ORR) was 23%, and (CBR) was 58%. The suggested maximum tolerated dose was
400 mg twice daily. Twenty-eight patients with gBRCAm had an ORR of 40% and clinical benefit
rate (CBR) of 68%. However, with limited anti-tumor effect of veliparib monotherapy, combination
therapies involving veliparib were initiated.
7.1.2. Combination Strategies
Veliparib has been widely studied in combination with several other regimens. Early phase I and
phase II trials studied veliparib in combination with carboplatin and paclitaxel (NCT00535119) [83],
veliparib in combination with doxorubicin and cyclophosphamide (NCT00740805) [84], veliparib
with cisplatin and vinorelbine (NCT01104259) [85], veliparib with carboplatin (NCT01251874) [86],
and veliparib with temozolomide (NCT01009788) [87]. In these early combination studies, a 73%
response rate was seen with veliparib in combination with cisplatin and vinorelbine in BRCA-mutated
TNBC [85], and modest response rates with the other aforementioned combinations, but adverse
events included neutropenia and thrombocytopenia [83–87].
BrighTNess is a phase III randomized, double-blind, placebo-controlled trial involving patients
with stage II–III TNBC treated with paclitaxel and/or veliparib with or without carboplatin
(NCT02032277) [88]. Patients who were treated with the triple combination therapy of paclitaxel,
carboplatin, and veliparib achieved pCR of 53% (168/316), compared to 31% (49/158) in patients who
received paclitaxel alone. Veliparib did not substantially increase toxicity, compared to patients who
had received carboplatin and experienced serious adverse events such as neutropenia, anemia, and
thrombocytopenia. Results of triple combination therapy were similar to results of treatment with
paclitaxel and carboplatin (58%, 92/160).
BROCADE 3 (NCT02163694) is a placebo-controlled, randomized phase III trial that is currently
open for patients with gBRCAm HER2-negative advanced or metastatic breast cancer. Patients receive
carboplatin and paclitaxel with or without veliparib. The estimated study completion date is May 2019.
7.2. Niraparib (MK4827)—Tesaro
Niraparib is a potent oral inhibitor of PARP-1 and PARP-2 with IC50 values of 3.8 and 2.1 nmol/L,
respectively [89,90]. Niraparib is approved by the FDA for maintenance treatment of patients with
recurrent high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer with
complete or partial response to platinum-based chemotherapy [91].
7.2.1. Monotherapy
In a phase I dose escalation study (NCT00749502) [92], four of 12 breast cancer patients were
BRCA1/2-mutant carriers. Two (50%) of the four BRCA mutant carriers had 30% and 50% partial
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response rate (PRR) to niraparib, respectively. PR lasted approximately three months at starting doses
of 210 and 150 mg/day. The most common adverse effect to niraparib therapy was anemia, nausea,
fatigue, and thrombocytopenia. The recommended phase 2 dose was 300 mg PO (per os, by mouth)
daily. Although a small sample size is noted, this study demonstrated that niraparib had durable
antitumor activity in BRCA-1/2 mutant carriers in patients with breast cancer [92]. The BRAVO (A Phase
III Trial of Niraparib Versus Physician’s Choice in HER2 Negative, Germline BRCA Mutation-positive
Breast Cancer Patients) study was initiated in late 2013 (NCT01905592). This randomized, open-label,
multicenter, controlled study is a comparison of progression-free survival (PFS) treated with niraparib
versus physician’s choice of chemotherapy (PCT) (eribulin, vinorelbine, gemcitabine, or capecitabine).
Niraparib is administered once daily during a 21-day cycle. Physician’s choice is administered on a
21-day cycle. A phase II study (NCT02826512) initiated in 2018 is planned to assess the feasibility of
niraparib in BRCA1-like, HER2-negative breast cancer patients.
7.2.2. Combination Strategies
A phase I/II study named TOPACIO (NCT02657889), initiated in March 2016, examines niraparib
used in combination with an anti-PD-1 monoclonal antibody, pembrolizumab (MK-3475), to treat
patients with advanced breast cancer, TNBC, or ovarian cancer. Phase I of the study involves
administering ascending doses of niraparib up to 300 mg/day orally on day one to 21 of a 21-day cycle,
with IV pembrolizumab 200 mg on day one of each 21-day cycle. In phase II, patients are administered
niraparib in combination with IV pembrolizumab 200 mg on day one of each 21-day cycle. This study’s
projected completion date is February 2019.
7.3. Olaparib (AZD2281, Ku-0059436, Lynparza)—AstraZeneca
7.3.1. Monotherapy
Olaparib was the first PARP inhibitor to be approved for cancer therapy. Phase I results in
2009 from Fong et al. demonstrated that olaparib had antitumor activity in patients with gBRCAm
ovarian and breast cancers and advanced solid tumors (NCT00516373) [76]. A subsequent phase II
trial (ICEBERG, NCT00494234) by Tutt et al. in patients with confirmed BRCA mutations showed a
favorable therapeutic index, providing proof of concept for the efficacy of olaparib, with 41% (11/27)
ORR in patients taking olaparib 400 mg BID [93]. Another early phase 2 study by Gelmon et al.
(NCT00679783) demonstrated that patients with TNBC had no OR, while those with ovarian cancer
had 41% OR [94]. A 2014 multicenter, open-label, noncomparative phase II clinical trial examined
the efficacy of olaparib monotherapy in patients with advanced, recurrent cancer with a germline
BRCA1/2 mutation. A total of 62 breast cancer patients were treated, and 60% of these breast cancer
patients had a BRCA1 mutation. A total of 12.9% of the breast cancer patients had a tumor response
rate, and 46.8% of patients achieved stable disease (SD) after ≥8 weeks olaparib treatment. Median
duration of response was 204 days. A total of 29% of patients were progression free at six months.
Median overall survival was 11 months, and 44.7% of patients were alive at 12 months. Anemia was
the most common ≥grade 3 adverse event [95].
7.3.2. Combination Strategies
In addition to numerous monotherapy studies, many studies now look at the response of
olaparib in combination with other cytotoxic drugs (Table 1). A 2014 phase I study showed that
BRCA1/2 breast cancer patients had a 71% response rate (12/17 patients) to olaparib (50 mg BID) and
cisplatin (60 mg/m2) combination therapy. Frequent grade 3 toxicities, such as neutropenia, anemia,
and leucopenia, rendered higher doses of olaparib (100 or 200 mg BID) and cisplatin (75 mg/m2)
intolerable [96].
In another recent phase I/Ib clinical trial, women with sporadic TNBC were treated with a
combination of olaparib and carboplatin. Twenty-eight patients were treated on a 21-day cycle, with
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400 mg olaparib twice daily on days one to seven and carboplatin on day one or two. The most
frequent non-hematologic events included nausea, fatigue, headache, gastroesophageal reflux disease,
and skin rashes. Hematologic toxicity was very common, with thrombocytopenia being the most
frequent occurrence in 50% of patients. The patients in this study were heavily pretreated; 75% of the
patients had been treated with over three prior therapies. Twelve of 28 patients achieved stable disease,
but nine of the patients had progressive disease. One patient who was an exceptional responder had
CR for 69+ months [97].
Olaparib also demonstrated anti-tumor activity when used in combination with rapamycin [98].
Another combination phase I study with olaparib and BKM120, a PI3-kinase inhibitor, demonstrated
clinical benefit for patients with high grade serious ovarian cancer or TNBC [99]. A phase 1 study
examining olaparib and cediranib (angiogenesis inhibitor) in ovarian cancer and TNBC determined the
recommended phase 2 dose of cediranib to be 30 mg daily and olaparib 200 mg BID [100]. Although
ORR in ovarian cancer patients was 44%, none of the breast cancer patients in this study achieved
clinical response.
Approval of olaparib for gBRCAm HER-2-negative breast cancer came following results from
the phase III OlympiAD clinical trial funded by AstraZeneca (NCT02000622) [70]. This was a
randomized, controlled, open-label, multicenter, international phase 3 trial. Patients received
olaparib tablets (300 mg twice daily), and 97 patients received standard therapy which consisted
of a single-agent chemotherapy (capecitabine, eribulin, or vinorelbine) according to the healthcare
provider’s recommendation. In the olaparib group, median PFS survival was ~67% longer than the
standard-therapy group (7.0 months with olaparib vs. 4.2 months with standard therapy). The response
rate was 59.9% in the olaparib group (100 patients out of 167) and 28.8% in the standard-therapy group
(19 of the 66 patients). Adverse events rated grade 3 or higher occurred in 36.6% of patients in the
olaparib group and 50.5% in the standard-therapy group.
Olaparib was approved by the FDA in January 2018 for treatment of gBRCAm, HER2-negative
metastatic breast cancers.
Table 1. Completed clinical trials with olaparib combination in breast cancer patients. (AUC = area
under the curve; BID = bis in die, twice a day; CBR = clinical benefit rate; CR = complete response;
ORR = objective response rate; PO = per os, by mouth; PR = partial response; QD = quaque die, once a
day; RP2D = recommended phase 2 dose; SD = stable disease; TNBC = triple negative breast cancer).
Therapeutic
Strategy; Phase
Patient Population;
Number of Breast
Patients
RP2D Results Grade 3–5Adverse Events
Identifier;
References
Olaparib with
carboplatin; I
BRCA1/2 mutation,
sporadic TNBC; 8
Olaparib 400 mg
PO BID days 1–7,
carboplatin AUC5
CR, 23 months
(2.4%, 1/8); PR, 10
months (75%, 6/8);
SD, 14 months
(12.5%, 1/8)
Neutropenia,
thrombo-cytopenia,
anemia
NCT01445418;
[101]
Olaparib with
carboplatin; I
TNBC; 10 (4
BRCA-mutant)
Olaparib 200 mg
PO BID for 7 days;
carboplatin
AUC4 q21d
CR, 32 months
(10%, 1/10); PR, ~9
months (30%, 3/10)
Neutropenia,
anemia
NCT01237067;
[102]
Olaparib with
cisplatin; I
Metastatic,
BRCA-mutant
Intermittent
olaparib 50 mg PO
BID days 1–5;
cisplatin 60 mg/m2
ORR (71%, 12/19)
Neutropenia,
anemia, lipase
elevation
NCT00782574;
[96]
Olaparib with
paclitaxel; I
Metastatic TNBC;
19
Olaparib 200 mg
PO BID; weekly
paclitaxel, 3 weeks
of 4-week cycle
PR (37%, 7/19);
SD ≥ weeks
(32%, 6/19)
Neutropenia NCT00707707;[103]
Olaparib with
cediranib; I Recurrent TNBC; 8
Olaparib 200 mg
PO BID; Cediranib
30 mg PO QD
No CR or PR;
SD > 24 weeks
(25%, 2/8)
Hypertension,
fatigue
NCT01116648;
[100]
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7.4. Rucaparib (AG-014699, PF-01367338)—Clovis Oncology
7.4.1. Monotherapy
Studies with rucaparib has predominantly involved ovarian cancer. However, there are multiple
clinical studies underway for breast cancer patients. RUBY is a single arm, open-label, multicenter
phase II trial currently recruiting patients with a BRCAness phenotype, as characterized by high
genomic LOH and/or a somatic BRCA mutation, including BRCA methylation or other epigenetic
mechanisms (NCT02505048) [104]. Of note, this trial excludes patients with a known BRCA1/2 germline
mutation. Patients will receive rucaparib 600 mg BID in 21-day cycles.
A recently closed phase II trial in patients with BRCA mutations and advanced and metastatic
breast cancer is a dose escalation trial with results pending (NCT00664781).
7.4.2. Combination Strategies
Following results from an in vitro study demonstrating that rucaparib induces cytotoxicity in
BRCA1/2-mutated cells [105], Drew et al. also investigated the effect of different dosing schedules of IV
and oral rucaparib in patients with advanced breast and ovarian cancer with gBRCAm. This phase II,
open-label, multicenter trial revealed that rucaparib was well-tolerated up to doses of 480 mg per day,
but no dose-limiting toxicities (DLT) were seen in the IV phase. Of 78 total patients, 15 had BRCA1
mutation-associated breast cancer and 12 had BRCA2 mutation-associated breast cancer. Although
there were no responders by tumor ORR in the breast cancer patients, 39% of the 23 breast cancer
patients did achieve stable disease (SD) at ≥12 weeks [105]. The results of this study were more
promising for the ovarian cancer patients, this study also demonstrated that continuous dosing orally
QID or BID is more effective at maintaining PARP inhibition, compared to an intermittent dosing
schedule [105,106]. The patients in this study achieved SD with the continuous dosing schedule.
A phase I study in patients with advanced solid tumors combined rucaparib with carboplatin
(NCT01009190) [107]. Twenty-two of the 85 patients enrolled had breast cancer, and one breast cancer
patient achieved CR. Across all cohorts, the disease control rate was 68.8%. The maximum tolerated
dose for the study was 240 mg per day when in combination with carboplatin.
An ongoing phase II trial investigates the effect of rucaparib and carboplatin in patients with
BRCA mutations and TNBC (NCT01074970).
7.5. Talazoparib (BMN-673)—Pfizer, BioMarin, Medivation
Talazoparib has been demonstrated to have a high degree of potency and oral bioavailability,
compared to the previously mentioned PARPi. In vitro studies from Shen et al. [108] show that
talazoparib selectively targeted tumor cells with BRCA1/2 mutations from 20- to 200-fold greater
potency than other PARP inhibitors. Significant antitumor effects were shown in vivo, and rats showed
greater than 40% oral bioavailability. Following these promising results, multiple clinical trials with
talazoparib monotherapy have been completed.
Monotherapy
A 2014 phase I trial examining antitumor activity of talazoparib (TALA) in gBRCAm breast cancer
and metastatic small-cell lung cancer patients showed a 39% (7/18) partial response rate and a 6%
(1/18) CR rate. Median PFS was 31 weeks for the breast cancer patients. The drug was administered on
day one and eight to 35, followed by daily dosing in four-week cycles. Dosing was 1.0 mg/day [109].
A phase I dose-escalation trial (NCT01286987), completed in 2017, involved administering TALA
either at nine dose levels, ranging from 0.025 to 1.1 mg/day (part 1), or at 1.0 mg/day (part 2) [110].
Of the 18 patients in part 1, those with a BRCA2 mutation had higher ORR (55%), compared to those
with a BRCA1 mutation (38%). Higher clinical benefit rate (CBR) was seen in patients with a BRCA2
versus BRCA1 mutation (91% versus 50%, respectively). Of the 14 breast cancer patients participating
in part 2, the ORR was 50% including one patient with a CR. Five of these patients had SD for 24 weeks,
J. Clin. Med. 2019, 8, 435 13 of 24
with a CBR of 86% lasting at least 24 weeks. Median PFS was 34.6 weeks. Additionally, although all
patients had deleterious BRCA1/2 mutations, patients with non-TNBC showed higher CBR (89% vs.
56%) and PFS (38.3 weeks vs. 20.4 weeks). Results from this phase I trial demonstrate the potency and
tolerability of talazoparib, paving the way for the phase II ABRAZO trial and phase III EMBRACA trial.
Patients with gBRCAm and advanced or metastatic breast cancer who had previously been
exposed to platinum or multiple prior cytotoxic regimens were enrolled in the phase 2 ABRAZO
trial (NCT02034916) [111]. Patients were divided into two cohorts: cohort 1 includes patients who
have had platinum-based therapy, and cohort 2 includes patients who have had ≥3 platinum-free
cytotoxic-based regimens. ORR was 21% in cohort 1 and 37% in cohort 2. Median PFS was 4.0 months
and 5.6 months for cohort 1 and cohort 2, respectively. Common adverse events included anemia,
fatigue, nausea, and diarrhea [111].
Prior to the EMBRACA clinical trial, Litton et al. conducted a feasibility study of administering
TALA before neoadjuvant chemotherapy for breast cancer patients with a deleterious BRCA
mutation [112]. These 13 patients had untreated, operable early-stage breast cancer. Median decrease in
tumor volume was 88%. Adverse events included fatigue, dizziness, nausea, neutropenia, anemia, and
thrombocytopenia. There were no grade 4 toxicities within the two months of talazoparib treatment.
Consequently, the study was expanded to six months of TALA prior to surgery. In addition, patients
were able to receive third-generation chemotherapy regimens after treatment.
The open-label, randomized, phase III EMBRACA trial compares TALA to physician’s choice of
therapy (PCT) in breast cancer patients with advanced disease and gBRCAm (NCT01945775) [113].
EMBRACA is the largest randomized trial evaluating a PARP inhibitor inpatients with gBRCAm
and advanced breast cancer. 288 patients were treated with TALA and 144 were treated with PCT.
Patients treated with TALA showed median PFS of 8.6 months compared to those treated with PCT of
5.6 months. Overall survival was 22.3 months in the TALA group and 19.5 months in the PCT group.
ORR for TALA was also statistically significant compared to PCT, at 62.6% versus 27.2, respectively.
Although grade 3–4 hematologic adverse events occurred more often in patients treated with TALA
than PCT (55% vs. 39%, respectively), TALA was generally well-tolerated and non-hematologic
adverse events were less common [114]. Additionally, participants in the EMBRACA phase 3 trial
showed significant delay in time to definitive clinically-meaningful deterioration (TTD) compared
to patients treated with physician’s choice of chemotherapy (PCT), according to results using the
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30
(EORTC QLQ-30) [115]. Based on the results of EMBRACA, on October 16, 2018, the U.S. FDA granted
approval of talazoparib for treatment of patients with BRCA-mutated, HER2-negative, advanced or
metastatic breast cancer.
8. Acquired Resistance to PARP Inhibitors
Although PARP inhibition is a promising therapeutic approach for BRCA-mutated breast cancers,
in some cases PARPi resistance can emerge, often via poorly understood mechanisms. One such
mechanism for PARPi resistance involves upregulation of Pgp, a drug efflux transporter [116].
AZD2461 is a next-generation PARP inhibitor that was synthesized as a poor substrate for Pgp.
This compound was developed in response to olaparib resistance and was derived from the same
chemical series as olaparib, the piperidine ether series [117].
Inactivation of p53-binding protein 1 (53BP1) has also been implicated in the development of
resistance to DNA-damaging agents by partially restoring HRR and rescuing proliferation defects in
BRCA1-deficient cells [118]. Data shows that reduced 53BP1 expression is correlated with TNBC and
in BRCA1/2 mutant tumors [118]. Expanding upon the role of 53BP1 in promoting PARPi cytotoxicity,
53BP1 inhibits HRR by impairing 5’ end resection [118,119]. More recent research points to the
interaction of 53BP1 with Rif1 to block resection of DNA breaks [120]. In a dominant negative 53BP1
construct, it was shown that 53BP1 suppression decreased NHEJ and increased HRR, which suggests
that 53BP1 may regulate the choice between the two repair pathways [121]. In an in vivo model, Jaspers
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et al. report resistance to PARPi due to somatic loss of 53BP1 and partial restoration of HRR [116].
Another in vivo model from Li et al. examines mutant BRCA1 lacking the N-terminal RING domain.
In cells expressing RING-less BRCA1, RAD51 foci still form in response to DNA damage. In mice
which carry exon 2-deleted forms of BRCA1, Li et al. found that ablation of 53BP1 rescues embryonic
lethality, although other BRCA1 phenotypes were not rescued by 53BP1 deletion. Their findings
provide support that 53BP1 and BRCA1 collaborate to maintain genomic integrity [122]. Further
implications toward resistance mechanisms can be drawn from these studies, as cells which lack 53BP1
and deletion of N-terminal-deleted BRCA1 isoforms can contribute to chemoresistance.
Given that RAD51 is an important component of the HRR pathway, elevated levels of RAD51
have been shown to contribute to PARPi resistance [123]. In this line of thinking, factors that increase
RAD51 levels may also contribute to resistance. Marzio et al. have recently demonstrated that early
mitotic inhibitor 1 (EMI1) activity targets RAD51 for degradation [124]. EMI1 is a substrate of S phase
kinase-associated protein 1 – cullin 1 – F-box protein (SCF) ubiquitin ligase, and functions as an APC/C
(anaphase-promoting complex or cyclosome) inhibitor [125,126]. In this 2019 study, Marzio et al. found
that EMI1 assembles a SCF ubiquitin ligase complex to target RAD51. They showed that a subset
of TNBC cells downregulate EMI1, which restores RAD51-dependent HRR, and these cells develop
resistance to PARPi. Additionally, they reconstituted EMI1 in cells and in a mouse model and found
that PARPi sensitivity was reestablished [124].
Genetic reversion of BRCA1 or BRCA2 mutations is another proposed mechanism of PARPi
resistance. In patients that had previously been treated with olaparib, and received initial response
followed by progressive tumor growth and a marked increase in CA15-3 (a carcinoma antigen),
a secondary BRCA2 c.9106C>G was detected. In a germline BRCA2 c.9106C>T mutation, a stop codon
is introduced. With this secondary point mutation, the BRCA2 open reading frame is potentially
restored, and the functional BRCA protein restores HRR [127]. Because the sample size in this study
was small, more preclinical data is needed to determine whether secondary mutations in BRCA are
dominant mechanisms for resistance to PARP inhibition.
Another theory of resistance to PARPi involves the upregulation of enhancer of zeste homolog 2
(EZH2), which is the catalytic component of the polycomb repressive complex 2 (PRC2) [128]. PRC2
and EZH2 are involved in histone methyltransferase activity and transcriptional repression. PARP
and EZH2 directly interact, and their interaction is upregulated by PARP-1 activation and inhibited by
PARPi. Results show that EZH2 and H3-K27me3 have increased expression in resistant cells. Thus,
a combination of PARPi and EZH2i has been shown to decrease the cancer stem cell population and
colony formation in vitro and tumor size in vivo [128]. Interestingly, ER+ breast cancer patients with
low H3K27me3 and high EZH2 have shorter overall survival and poor prognosis [129].
A very recent investigation has identified point mutations in PARP-1, which confer PARPi
resistance [130]. The researchers first confirmed that ablation of PARP-1 expression did, in fact,
hinder trapping of PARP-1 and confers PARPi resistance. The resistance was due to in-frame PARP-1
mutations in Parp1, which disrupt the interaction of zinc finger (ZnF) domains at the site of DNA
and PARP-1. Using a CRISPR-Cas9 screen, they identified candidate PARP-1 amino acid residues
associated with resistance, K119 and S120, which are involved in the binding of DNA residues to the
second ZnF domain of PARP-1. Mutations were also identified outside of the ZnF domain, such as
those in amino acid residues in the DNA-binding and catalytic domains [130]. Additionally, it has
been shown that PARP catalytic activity is increased upon phosphorylation of PARP-1 on amino acid
Tyr907. This in turn reduces PARPi binding [131].
Several research groups point to increased replication fork stability as a contributor to PARPi
resistance in BRCA1/2-deficient cancers. In the presence of a DNA strand break and the absence of
PARP-mediated DNA repair, replication forks collapse into a DSB [29]. However, when the replication
fork is stabilized and alternate mechanisms of repair dominate, resistance to PARPi occurs. Increased
replication fork stability may occur through loss of PTIP (Pax2 transactivation domain-interacting
protein, an HRR protein) [132], restoration of HR [133], or through the EZH2/MUS81 axis [134].
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The EZH2/MUS81 axis characterizes the recruitment of the MUS81 nuclease when EZH2 localizes at
stalled replication forks and increases methylation of H3K27. When EZH2 levels are low; however,
methylation is reduced and replication forks are stabilized as MUS81 recruitment is prevented [134].
Additional proposed mechanisms of resistance include increased expression of miR-493-5p,
which induces resistance to platinum and PARPi [135], and also depletion of PARG, the major enzyme
involved in the catabolism of PARP [136]. Given many recent discoveries in the field of PARPi
resistance, further investigation is warranted to improve treatment strategies for cancer patients.
The existence of multiple mechanisms of resistance to PARPi highlights the need for functional
biomarkers and strategies involving combination treatment.
9. Conclusions
Because breast cancer is a widely heterogeneous disease, treatment is complicated and often
involves multiple therapeutic modalities, such as chemotherapy, surgery, and radiation. Although
PARP inhibition is a promising therapeutic strategy to treat breast cancer, PARP inhibitors have clinical
activity restricted to a small category of patients with BRCA mutations. The challenge is to determine
the differences in breast cancer cell line responsiveness to PARP inhibition. To develop personalized
therapeutic targets, detailed characterization of breast cancer cells is required, along with the use of
predictive biomarkers and diagnostic methods mentioned in this review. To complicate matters further,
present studies mentioned in this review suggest that PARPi sensitivity is not restricted to breast
cancer with BRCA mutations. With two PARPi approved by the FDA to treat breast cancer, the future
is promising for the development of other PARP inhibitors for targeted therapy. Clinical studies are
underway examining PARPi as neoadjuvant therapy, as monotherapy, and in combination therapy.
Author Contributions: Writing—original draft preparation and revisions, M.Y.K., Y.W., J.V.V.; literature review,
M.Y.K.,Y.W., J.V.V.; figure generation, M.Y.K.; writing—review and editing, M.Y.K., Y.W., and J.V.V.
Funding: Research reported was supported by the National Cancer Institute under award number U54CA143931
and Accelerating Excellence in Translational Sciences (AXIS) Center-#U54MD007598, NIMHD
Conflicts of Interest: The authors declare no conflicts of interest.
Abbreviations
aNHEJ alternative non-homologous end-joining
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DNMTi DNA methyltransferase inhibitor
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RER ribonucleotide excision repair
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